Where Are They Now? Anita Kumar, MD
Dr. Anita Kumar is a medical oncologist at
Memorial Sloan Kettering Cancer Center (MSK)
and Regional Care Network Medical Site Director at MSK Basking Ridge, N.J.
News
A Pioneering Spirit
Dr. Eduardo Sotomayor is embarking on a new and exciting challenge
in his career that will combine his pioneering work in cancer
immunology and dedication to providing quality cancer care for all
patients.
Updates from the 2021 American Society of Hematology Annual Meeting
The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting, with more than 70 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific Advisory Board (SAB) and grantees, presenting abstracts at the conference.
ASH 2021: Pivotal Data on CAR T Cell Therapy and Emerging Construct Presented at ASH
Investigation into the use of chimeric antigen receptor (CAR) T cell therapies has expanded rapidly in recent years, including for hematologic malignancies. Results from several key studies were presented at the 2021 Annual ASH Meeting, which demonstrated the use of these emerging therapies in multiple lines of therapy, new disease states, and using novel constructs to enhance responses.
ASH 2021: Polatuzumab Vedotin Reduces Risk for Disease Progression in Previously Untreated Diffuse Large B-Cell Lymphoma
In the phase III POLARIX study, a team of investigators led by LRF Scientific Advisory Board (SAB) member Christopher R. Flowers, MD, MSc of the University of Texas MD Anderson Cancer Center compared the efficacy of standard R-CHOP with that of a modified drug regimen, in which vincristine was replaced with the antibody-drug conjugate polatuzumab vedotin (pola-R-CHP).
ASH 2021: BTG1 Mutation Is Associated with Aggressive Lymphomagenesis in Human and Animal Models of Diffuse Large B-Cell Lymphoma
A recurrent mutation in BTG1 is associated with a “super- competitive” B-cell phenotype in both mice and humans and may promote the development of aggressive diffuse large B-cell lymphoma (DLBCL), according to research, funded in part by LRF, presented by LRF grantee Coraline Mlynarczyk, PhD, of Weill Cornell Medicine.
ASH 2021: Minimal Residual Disease Kinetics Identified as a Predictor of Zanubrutinib-Obinutuzumab-Venetoclax Treatment Response in CLL
Minimal residual disease (MRD) kinetics were found to be predictive of achievement and durability of undetectable MRD with zanubrutinib-obinutuzumab-venetoclax (BOVen) treatment in patients with chronic lymphocytic leukemia (CLL), according to trial results presented by LRF grantee Jacob D. Soumerai, MD of Massachusetts General Hospital Cancer Center.
ASH 2021: High MCL35 Score Is Predictive of Poor Survival in Older Patients with Mantle Cell Lymphoma Treated with Bendamustine-Rituximab
In a study funded in part by LRF and led by LRF Scientific Advisory Board (SAB) and Mantle Cell Lymphoma Consortium (MCLC) member Lisa M. Rimsza, MD, of Mayo Clinic, Phoenix, researchers examined the prognostic value of the MCL35 assay in older patients (aged 65-93) with MCL who were treated with frontline bendamustine (Treanda) plus rituximab (Rituxan).
ASH 2021: No Difference in Survival Among Black Patients with Cutaneous T-Cell Lymphomas in Multicenter Analysis
Large registry studies in the United States have revealed lower rates of survival and a propensity for high-risk features in Black patients with mycosis fungoides and Sézary syndrome compared with other races and ethnicities.
ASH 2021: Pembrolizumab Plus HDAC Inhibition Exhibits High Response Rates for Hodgkin Lymphoma in Early Study
Response rates to pembrolizumab (Keytruda) plus vorinostat (Zolinza), a histone deacetylase (HDAC) inhibitor, were high in anti-PD1 naïve/sensitivity relapsed/refractory Hodgkin lymphoma (HL), according to a study funded in part by LRF and presented by LRF grantee Alex F. Herrera, MD, of City of Hope.
Stay informed with news, alerts and other resources.
